Cargando…
Rifaximin Use, Adherence and Persistence in Patients with Hepatic Encephalopathy: A Real-World Study in the South of Italy
Real-world data on the therapeutic management of hepatic encephalopathy (HE) patients are limited. The aim of this study was to evaluate the HE medications prescribed in an Italian cohort of HE patients post-discharge and to assess the real-world rifaximin adherence and persistence over 1 year. An o...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10342713/ https://www.ncbi.nlm.nih.gov/pubmed/37445550 http://dx.doi.org/10.3390/jcm12134515 |
_version_ | 1785072565065089024 |
---|---|
author | Pandico, Fulvio Citarella, Anna Cammarota, Simona Bernardi, Francesca Futura Claar, Ernesto Coppola, Carmine Cozzolino, Marianna De Rosa, Federica Di Gennaro, Massimo Fogliasecca, Marianna Giordana, Roberta Pacella, Daniela Russo, Alessandro Salerno, Vito Scafa, Luca Trama, Ugo |
author_facet | Pandico, Fulvio Citarella, Anna Cammarota, Simona Bernardi, Francesca Futura Claar, Ernesto Coppola, Carmine Cozzolino, Marianna De Rosa, Federica Di Gennaro, Massimo Fogliasecca, Marianna Giordana, Roberta Pacella, Daniela Russo, Alessandro Salerno, Vito Scafa, Luca Trama, Ugo |
author_sort | Pandico, Fulvio |
collection | PubMed |
description | Real-world data on the therapeutic management of hepatic encephalopathy (HE) patients are limited. The aim of this study was to evaluate the HE medications prescribed in an Italian cohort of HE patients post-discharge and to assess the real-world rifaximin adherence and persistence over 1 year. An observation retrospective study was conducted using data retrieved from outpatient pharmaceutical databases and hospital discharge records of the Campania region. For all subjects hospitalized for HE during 2019 (cohort 1), the HE medications prescribed within 60 days after discharge were evaluated. Adherence (proportion of days covered, PDC) and persistence were estimated for rifaximin 550 mg incident users over 1 year (cohort 2). Patients with PDC ≥80% were considered adherents. Persistence was defined as the period of time from the first rifaximin prescription to the date of discontinuation. Discontinuation was assessed using the permissible gap method. In cohort 1, 544 patients were identified; 58.5% received rifaximin while 15.6% only received non-absorbable disaccharides and 25.9% did not receive any HE medications. In cohort 2, 650 users were selected; only 54.5% were adherents and 35% were persistent users at 1 year. This real-world study highlights that quality improvement in therapeutic management is needed to potentially improve the outcomes of HE patients. |
format | Online Article Text |
id | pubmed-10342713 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-103427132023-07-14 Rifaximin Use, Adherence and Persistence in Patients with Hepatic Encephalopathy: A Real-World Study in the South of Italy Pandico, Fulvio Citarella, Anna Cammarota, Simona Bernardi, Francesca Futura Claar, Ernesto Coppola, Carmine Cozzolino, Marianna De Rosa, Federica Di Gennaro, Massimo Fogliasecca, Marianna Giordana, Roberta Pacella, Daniela Russo, Alessandro Salerno, Vito Scafa, Luca Trama, Ugo J Clin Med Article Real-world data on the therapeutic management of hepatic encephalopathy (HE) patients are limited. The aim of this study was to evaluate the HE medications prescribed in an Italian cohort of HE patients post-discharge and to assess the real-world rifaximin adherence and persistence over 1 year. An observation retrospective study was conducted using data retrieved from outpatient pharmaceutical databases and hospital discharge records of the Campania region. For all subjects hospitalized for HE during 2019 (cohort 1), the HE medications prescribed within 60 days after discharge were evaluated. Adherence (proportion of days covered, PDC) and persistence were estimated for rifaximin 550 mg incident users over 1 year (cohort 2). Patients with PDC ≥80% were considered adherents. Persistence was defined as the period of time from the first rifaximin prescription to the date of discontinuation. Discontinuation was assessed using the permissible gap method. In cohort 1, 544 patients were identified; 58.5% received rifaximin while 15.6% only received non-absorbable disaccharides and 25.9% did not receive any HE medications. In cohort 2, 650 users were selected; only 54.5% were adherents and 35% were persistent users at 1 year. This real-world study highlights that quality improvement in therapeutic management is needed to potentially improve the outcomes of HE patients. MDPI 2023-07-06 /pmc/articles/PMC10342713/ /pubmed/37445550 http://dx.doi.org/10.3390/jcm12134515 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Pandico, Fulvio Citarella, Anna Cammarota, Simona Bernardi, Francesca Futura Claar, Ernesto Coppola, Carmine Cozzolino, Marianna De Rosa, Federica Di Gennaro, Massimo Fogliasecca, Marianna Giordana, Roberta Pacella, Daniela Russo, Alessandro Salerno, Vito Scafa, Luca Trama, Ugo Rifaximin Use, Adherence and Persistence in Patients with Hepatic Encephalopathy: A Real-World Study in the South of Italy |
title | Rifaximin Use, Adherence and Persistence in Patients with Hepatic Encephalopathy: A Real-World Study in the South of Italy |
title_full | Rifaximin Use, Adherence and Persistence in Patients with Hepatic Encephalopathy: A Real-World Study in the South of Italy |
title_fullStr | Rifaximin Use, Adherence and Persistence in Patients with Hepatic Encephalopathy: A Real-World Study in the South of Italy |
title_full_unstemmed | Rifaximin Use, Adherence and Persistence in Patients with Hepatic Encephalopathy: A Real-World Study in the South of Italy |
title_short | Rifaximin Use, Adherence and Persistence in Patients with Hepatic Encephalopathy: A Real-World Study in the South of Italy |
title_sort | rifaximin use, adherence and persistence in patients with hepatic encephalopathy: a real-world study in the south of italy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10342713/ https://www.ncbi.nlm.nih.gov/pubmed/37445550 http://dx.doi.org/10.3390/jcm12134515 |
work_keys_str_mv | AT pandicofulvio rifaximinuseadherenceandpersistenceinpatientswithhepaticencephalopathyarealworldstudyinthesouthofitaly AT citarellaanna rifaximinuseadherenceandpersistenceinpatientswithhepaticencephalopathyarealworldstudyinthesouthofitaly AT cammarotasimona rifaximinuseadherenceandpersistenceinpatientswithhepaticencephalopathyarealworldstudyinthesouthofitaly AT bernardifrancescafutura rifaximinuseadherenceandpersistenceinpatientswithhepaticencephalopathyarealworldstudyinthesouthofitaly AT claarernesto rifaximinuseadherenceandpersistenceinpatientswithhepaticencephalopathyarealworldstudyinthesouthofitaly AT coppolacarmine rifaximinuseadherenceandpersistenceinpatientswithhepaticencephalopathyarealworldstudyinthesouthofitaly AT cozzolinomarianna rifaximinuseadherenceandpersistenceinpatientswithhepaticencephalopathyarealworldstudyinthesouthofitaly AT derosafederica rifaximinuseadherenceandpersistenceinpatientswithhepaticencephalopathyarealworldstudyinthesouthofitaly AT digennaromassimo rifaximinuseadherenceandpersistenceinpatientswithhepaticencephalopathyarealworldstudyinthesouthofitaly AT fogliaseccamarianna rifaximinuseadherenceandpersistenceinpatientswithhepaticencephalopathyarealworldstudyinthesouthofitaly AT giordanaroberta rifaximinuseadherenceandpersistenceinpatientswithhepaticencephalopathyarealworldstudyinthesouthofitaly AT pacelladaniela rifaximinuseadherenceandpersistenceinpatientswithhepaticencephalopathyarealworldstudyinthesouthofitaly AT russoalessandro rifaximinuseadherenceandpersistenceinpatientswithhepaticencephalopathyarealworldstudyinthesouthofitaly AT salernovito rifaximinuseadherenceandpersistenceinpatientswithhepaticencephalopathyarealworldstudyinthesouthofitaly AT scafaluca rifaximinuseadherenceandpersistenceinpatientswithhepaticencephalopathyarealworldstudyinthesouthofitaly AT tramaugo rifaximinuseadherenceandpersistenceinpatientswithhepaticencephalopathyarealworldstudyinthesouthofitaly |